{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T17:06:46Z","timestamp":1772644006515,"version":"3.50.1"},"reference-count":164,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-025-01909-7","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T10:16:30Z","timestamp":1764929790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long non-coding RNAs and VEGF in ovarian cancer: mechanisms and therapeutic potential"],"prefix":"10.1186","volume":"19","author":[{"given":"Alqassem H.","family":"Abuarqoub","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8851-5783","authenticated-orcid":false,"given":"Waleed K.","family":"Abdulsahib","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. Renuka","family":"Jyothi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priya Priyadarshini","family":"Nayak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish Singh","family":"Chauhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siya","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fadhil Faez","family":"Sead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nodira","family":"Zakirova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"crossref","unstructured":"Basu S, Nadhan R, Dhanasekaran DN. Long Non-Coding RNAs in ovarian cancer: mechanistic insights and clinical applications. Cancers (Basel). 2025;17(3).","DOI":"10.3390\/cancers17030472"},{"key":"1909_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/IJWH.S197604","volume":"11","author":"Z Momenimovahed","year":"2019","unstructured":"Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019;11:287\u201399.","journal-title":"Int J Womens Health"},{"issue":"28","key":"1909_CR3","doi-asserted-by":"publisher","first-page":"44719","DOI":"10.18632\/oncotarget.8089","volume":"7","author":"M Meryet-Figui\u00e8re","year":"2016","unstructured":"Meryet-Figui\u00e8re M, Lambert B, Gauduchon P, Vigneron N, Brotin E, Poulain L, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016;7(28):44719\u201334.","journal-title":"Oncotarget"},{"key":"1909_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111240","volume":"120","author":"W Zhou","year":"2024","unstructured":"Zhou W, Zeng T, Chen J, Tang X, Yuan Y, Hu D, et al. Aberrant angiogenic signaling pathways: accomplices in ovarian cancer progression and treatment. Cell Signal. 2024;120:111240.","journal-title":"Cell Signal"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"1147717","DOI":"10.3389\/fphar.2023.1147717","volume":"14","author":"C Mei","year":"2023","unstructured":"Mei C, Gong W, Wang X, Lv Y, Zhang Y, Wu S, et al. Anti-angiogenic therapy in ovarian cancer: current understandings and prospects of precision medicine. Front Pharmacol. 2023;14:1147717.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1909_CR6","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01077-y","volume":"15","author":"QA Naseer","year":"2024","unstructured":"Naseer QA, Malik A, Zhang F, Chen S. Exploring the enigma: history, present, and future of long non-coding RNAs in cancer. Discover Oncol. 2024;15(1):214.","journal-title":"Discover Oncol"},{"issue":"12","key":"1909_CR7","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2018.06.10","volume":"6","author":"MA Diamantopoulos","year":"2018","unstructured":"Diamantopoulos MA, Tsiakanikas P, Scorilas A. Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Ann Transl Med. 2018;6(12):241.","journal-title":"Ann Transl Med"},{"issue":"2","key":"1909_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00439-023-02635-0","volume":"143","author":"SH Malgundkar","year":"2024","unstructured":"Malgundkar SH, Tamimi Y. The pivotal role of long non-coding RNAs as potential biomarkers and modulators of chemoresistance in ovarian cancer (OC). Hum Genet. 2024;143(2):107\u201324.","journal-title":"Hum Genet"},{"issue":"7","key":"1909_CR9","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.7150\/ijbs.40769","volume":"16","author":"W Lin","year":"2020","unstructured":"Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang S, et al. LncRNAs regulate metabolism in cancer. Int J Biol Sci. 2020;16(7):1194\u2013206.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"1909_CR10","doi-asserted-by":"publisher","first-page":"e1003569","DOI":"10.1371\/journal.pgen.1003569","volume":"9","author":"MJ Hangauer","year":"2013","unstructured":"Hangauer MJ, Vaughn IW, McManus MT. Pervasive transcription of the human genome produces thousands of previously unidentified long intergenic noncoding RNAs. PLoS Genet. 2013;9(6):e1003569.","journal-title":"PLoS Genet"},{"issue":"4","key":"1909_CR11","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.ccell.2016.03.010","volume":"29","author":"AM Schmitt","year":"2016","unstructured":"Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452\u201363.","journal-title":"Cancer Cell"},{"key":"1909_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175586","volume":"949","author":"S Ghalehbandi","year":"2023","unstructured":"Ghalehbandi S, Yuzugulen J, Pranjol MZI, Pourgholami MH. The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. Eur J Pharmacol. 2023;949:175586.","journal-title":"Eur J Pharmacol"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"156908","DOI":"10.1016\/j.cyto.2025.156908","volume":"189","author":"Z Shi","year":"2025","unstructured":"Shi Z, Kuai M, Li B, Akowuah CF, Wang Z, Pan Y, et al. The role of VEGF in cancer angiogenesis and tumorigenesis: insights for anti-VEGF therapy. Cytokine. 2025;189:156908.","journal-title":"Cytokine"},{"issue":"1\u20132","key":"1909_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10555-011-9337-5","volume":"31","author":"S Masoumi Moghaddam","year":"2012","unstructured":"Masoumi Moghaddam S, Amini A, Morris DL, Pourgholami MH. Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer. Cancer Metastasis Rev. 2012;31(1\u20132):143\u201362.","journal-title":"Cancer Metastasis Rev"},{"issue":"26","key":"1909_CR15","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","volume":"365","author":"RA Burger","year":"2011","unstructured":"Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473\u201383.","journal-title":"N Engl J Med"},{"key":"1909_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1332528","volume":"14","author":"Z Hu","year":"2024","unstructured":"Hu Z, Yuan L, Yang X, Yi C, Lu J. The roles of long non-coding RNAs in ovarian cancer: from functions to therapeutic implications. Front Oncol. 2024;14:1332528.","journal-title":"Front Oncol"},{"issue":"11","key":"1909_CR17","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrm3679","volume":"14","author":"S Geisler","year":"2013","unstructured":"Geisler S, Coller J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts. Nat Rev Mol Cell Biol. 2013;14(11):699\u2013712.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1909_CR18","doi-asserted-by":"crossref","unstructured":"Braga EA, Fridman MV, Moscovtsev AA, Filippova EA, Dmitriev AA, Kushlinskii NE. LncRNAs in ovarian cancer Progression, Metastasis, and main pathways: CeRNA and alternative mechanisms. Int J Mol Sci. 2020;21(22).","DOI":"10.3390\/ijms21228855"},{"key":"1909_CR19","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2020.12.042","volume":"502","author":"V Bhardwaj","year":"2021","unstructured":"Bhardwaj V, Tan YQ, Wu MM, Ma L, Zhu T, Lobie PE, et al. Long non-coding RNAs in recurrent ovarian cancer: theranostic perspectives. Cancer Lett. 2021;502:97\u2013107.","journal-title":"Cancer Lett"},{"key":"1909_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.biocel.2015.05.006","volume":"67","author":"I van Kruijsbergen","year":"2015","unstructured":"van Kruijsbergen I, Hontelez S, Veenstra GJC. Recruiting polycomb to chromatin. Int J Biochem Cell Biol. 2015;67:177\u201387.","journal-title":"Int J Biochem Cell Biol"},{"issue":"5992","key":"1909_CR21","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1126\/science.1192002","volume":"329","author":"MC Tsai","year":"2010","unstructured":"Tsai MC, Manor O, Wan Y, Mosammaparast N, Wang JK, Lan F, et al. Long noncoding RNA as modular scaffold of histone modification complexes. Science. 2010;329(5992):689\u201393.","journal-title":"Science"},{"issue":"3","key":"1909_CR22","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1159\/000485395","volume":"44","author":"T Worku","year":"2017","unstructured":"Worku T, Bhattarai D, Ayers D, Wang K, Wang C, Rehman ZU, et al. Long Non-Coding RNAs: the New Horizon of Gene Regulation in Ovarian Cancer. Cell Physiol Biochem. 2017;44(3):948\u201366.","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"1909_CR23","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s12253-019-00614-3","volume":"25","author":"A Al-Rugeebah","year":"2019","unstructured":"Al-Rugeebah A, Alanazi M, Parine NR. MEG3: an oncogenic long Non-coding RNA in different cancers. Pathol Oncol Res. 2019;25(3):859\u201374.","journal-title":"Pathol Oncol Res"},{"issue":"4","key":"1909_CR24","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.tibs.2011.12.003","volume":"37","author":"JF Kugel","year":"2012","unstructured":"Kugel JF, Goodrich JA. Non-coding RNAs: key regulators of mammalian transcription. Trends Biochem Sci. 2012;37(4):144\u201351.","journal-title":"Trends Biochem Sci"},{"issue":"5","key":"1909_CR25","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41580-023-00694-9","volume":"25","author":"J Ferrer","year":"2024","unstructured":"Ferrer J, Dimitrova N. Transcription regulation by long non-coding rnas: mechanisms and disease relevance. Nat Rev Mol Cell Biol. 2024;25(5):396\u2013415.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"26","key":"1909_CR26","doi-asserted-by":"publisher","first-page":"18648","DOI":"10.18632\/oncotarget.24307","volume":"9","author":"G Hu","year":"2018","unstructured":"Hu G, Niu F, Humburg BA, Liao K, Bendi S, Callen S, et al. Molecular mechanisms of long noncoding RNAs and their role in disease pathogenesis. Oncotarget. 2018;9(26):18648\u201363.","journal-title":"Oncotarget"},{"issue":"W1","key":"1909_CR27","doi-asserted-by":"publisher","first-page":"W176","DOI":"10.1093\/nar\/gkw443","volume":"44","author":"P Furi\u00f3-Tar\u00ed","year":"2016","unstructured":"Furi\u00f3-Tar\u00ed P, Tarazona S, Gabald\u00f3n T, Enright AJ, Conesa A. SpongeScan: a web for detecting MicroRNA binding elements in LncRNA sequences. Nucleic Acids Res. 2016;44(W1):W176-80.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"1909_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.molcel.2013.08.027","volume":"52","author":"AN Kallen","year":"2013","unstructured":"Kallen AN, Zhou XB, Xu J, Qiao C, Ma J, Yan L, et al. The imprinted H19 lncRNA antagonizes let-7 microRNAs. Mol Cell. 2013;52(1):101\u201312.","journal-title":"Mol Cell"},{"key":"1909_CR29","doi-asserted-by":"crossref","unstructured":"Zhang X, Wang W, Zhu W, Dong J, Cheng Y, Yin Z et al. Mechanisms and functions of long Non-Coding RNAs at multiple regulatory levels. Int J Mol Sci. 2019;20(22).","DOI":"10.3390\/ijms20225573"},{"issue":"1","key":"1909_CR30","first-page":"81","volume":"7","author":"E Guzel","year":"2020","unstructured":"Guzel E, Okyay TM, Yalcinkaya B, Karacaoglu S, Gocmen M, Akcakuyu MH. Tumor suppressor and oncogenic role of long non-coding RNAs in cancer. North Clin Istanb. 2020;7(1):81\u20136.","journal-title":"North Clin Istanb"},{"issue":"3","key":"1909_CR31","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.trecan.2017.01.005","volume":"3","author":"AA Cluntun","year":"2017","unstructured":"Cluntun AA, Lukey MJ, Cerione RA, Locasale JW. Glutamine metabolism in cancer: understanding the heterogeneity. Trends Cancer. 2017;3(3):169\u201380.","journal-title":"Trends Cancer"},{"issue":"1","key":"1909_CR32","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12935-021-01926-8","volume":"21","author":"Y Guo","year":"2021","unstructured":"Guo Y, Lv B, Liu R, Dai Z, Zhang F, Liang Y, et al. Role of LncRNAs in regulating cancer amino acid metabolism. Cancer Cell Int. 2021;21(1):209.","journal-title":"Cancer Cell Int"},{"issue":"4","key":"1909_CR33","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.molcel.2016.01.015","volume":"61","author":"RS Redis","year":"2016","unstructured":"Redis RS, Vela LE, Lu W, Ferreira de Oliveira J, Ivan C, Rodriguez-Aguayo C, et al. Allele-Specific reprogramming of cancer metabolism by the long Non-coding RNA CCAT2. Mol Cell. 2016;61(4):520\u201334.","journal-title":"Mol Cell"},{"issue":"2","key":"1909_CR34","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22(2):96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"1909_CR35","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ccr.2014.07.009","volume":"26","author":"X Hu","year":"2014","unstructured":"Hu X, Feng Y, Zhang D, Zhao SD, Hu Z, Greshock J, et al. A functional genomic approach identifies FAL1 as an oncogenic long noncoding RNA that associates with BMI1 and represses p21 expression in cancer. Cancer Cell. 2014;26(3):344\u201357.","journal-title":"Cancer Cell"},{"issue":"2","key":"1909_CR36","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1158\/0008-5472.CAN-14-3607","volume":"76","author":"Y Li","year":"2016","unstructured":"Li Y, Wang Z, Shi H, Li H, Li L, Fang R, et al. HBXIP and LSD1 scaffolded by lncRNA Hotair mediate transcriptional activation by c-Myc. Cancer Res. 2016;76(2):293\u2013304.","journal-title":"Cancer Res"},{"issue":"1","key":"1909_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.gpb.2015.09.006","volume":"14","author":"Y Fang","year":"2016","unstructured":"Fang Y, Fullwood MJ. Roles, functions, and mechanisms of long non-coding RNAs in cancer. Genomics Proteomics Bioinf. 2016;14(1):42\u201354.","journal-title":"Genomics Proteomics Bioinf"},{"key":"1909_CR38","doi-asserted-by":"crossref","unstructured":"Lozano-Romero A, Astudillo-de la Vega H, Terrones-Gurrola M, Marchat LA, Hern\u00e1ndez-Sotelo D, Salinas-Vera YM et al. HOX transcript antisense RNA HOTAIR abrogates vasculogenic mimicry by targeting the AngiomiR-204\/FAK axis in triple negative breast cancer cells. Noncoding RNA. 2020;6(2).","DOI":"10.3390\/ncrna6020019"},{"issue":"1","key":"1909_CR39","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12943-023-01765-3","volume":"22","author":"GSR Raju","year":"2023","unstructured":"Raju GSR, Pavitra E, Bandaru SS, Varaprasad GL, Nagaraju GP, Malla RR, et al. HOTAIR: a potential metastatic, drug-resistant and prognostic regulator of breast cancer. Mol Cancer. 2023;22(1):65.","journal-title":"Mol Cancer"},{"issue":"1","key":"1909_CR40","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1186\/s12935-024-03612-x","volume":"24","author":"M Nazari","year":"2024","unstructured":"Nazari M, Babakhanzadeh E, Mollazadeh A, Ahmadzade M, Mohammadi Soleimani E, Hajimaqsoudi E. HOTAIR in cancer: diagnostic, prognostic, and therapeutic perspectives. Cancer Cell Int. 2024;24(1):415.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"1909_CR41","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.yexcr.2015.03.005","volume":"333","author":"J-j Qiu","year":"2015","unstructured":"Qiu J-j, Wang Y, Ding J-x, Jin H-y, Yang G, Hua K-q. The long non-coding RNA HOTAIR promotes the proliferation of serous ovarian cancer cells through the regulation of cell cycle arrest and apoptosis. Exp Cell Res. 2015;333(2):238\u201348.","journal-title":"Exp Cell Res"},{"issue":"11","key":"1909_CR42","doi-asserted-by":"publisher","first-page":"1523","DOI":"10.1080\/15476286.2019.1702283","volume":"17","author":"S Oncul","year":"2020","unstructured":"Oncul S, Amero P, Rodriguez-Aguayo C, Calin GA, Sood AK, Lopez-Berestein G. Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. RNA Biol. 2020;17(11):1523\u201334.","journal-title":"RNA Biol"},{"key":"1909_CR43","doi-asserted-by":"publisher","first-page":"13489","DOI":"10.2147\/CMAR.S286804","volume":"12","author":"H Liao","year":"2020","unstructured":"Liao H, Chen Q, Xiao J. Reflections on the role of Malat1 in gynecological cancer. Cancer Manag Res. 2020;12:13489\u2013500.","journal-title":"Cancer Manag Res"},{"issue":"5","key":"1909_CR44","doi-asserted-by":"publisher","first-page":"e0155250","DOI":"10.1371\/journal.pone.0155250","volume":"11","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Xu X, Lv H, Wen Q, Li J, Tan L, et al. The long noncoding RNA MALAT-1 is highly expressed in ovarian cancer and induces cell growth and migration. PLoS One. 2016;11(5):e0155250.","journal-title":"PLoS One"},{"issue":"14","key":"1909_CR45","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.7150\/ijbs.28048","volume":"14","author":"JJ Qiu","year":"2018","unstructured":"Qiu JJ, Lin XJ, Tang XY, Zheng TT, Lin YY, Hua KQ. Exosomal metastasis\u2013associated lung adenocarcinoma transcript 1 promotes angiogenesis and predicts poor prognosis in epithelial ovarian cancer. Int J Biol Sci. 2018;14(14):1960\u201373.","journal-title":"Int J Biol Sci"},{"issue":"6","key":"1909_CR46","first-page":"2644","volume":"39","author":"Q Lin","year":"2018","unstructured":"Lin Q, Guan W, Ren W, Zhang L, Zhang J, Xu G. MALAT1 affects ovarian cancer cell behavior and patient survival. Oncol Rep. 2018;39(6):2644\u201352.","journal-title":"Oncol Rep"},{"issue":"7","key":"1909_CR47","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1111\/cas.13647","volume":"109","author":"Y Liu","year":"2018","unstructured":"Liu Y, Wang Y, Fu X, Lu Z. Long non-coding RNA NEAT 1 promoted ovarian cancer cells\u2019 metastasis through regulation of miR\u2010382\u20103p\/ROCK 1 axial. Cancer Sci. 2018;109(7):2188\u201398.","journal-title":"Cancer Sci"},{"issue":"3","key":"1909_CR48","doi-asserted-by":"publisher","first-page":"496","DOI":"10.4161\/rna.8.3.14800","volume":"8","author":"JM Silva","year":"2011","unstructured":"Silva JM, Boczek NJ, Berres MW, Ma X, Smith DI. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011;8(3):496\u2013505.","journal-title":"RNA Biol"},{"key":"1909_CR49","first-page":"92","volume":"17","author":"Z Li","year":"2019","unstructured":"Li Z, Niu H, Qin Q, Yang S, Wang Q, Yu C, et al. LncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143\/FOSL2-signaling pathway in ovarian cancer. Mol Ther. 2019;17:92\u2013101.","journal-title":"Mol Ther"},{"issue":"6","key":"1909_CR50","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.3892\/ijo.2015.2943","volume":"46","author":"JJ Qiu","year":"2015","unstructured":"Qiu JJ, Lin YY, Ding JX, Feng WW, Jin HY, Hua KQ. Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion\/metastasis in serous ovarian cancer. Int J Oncol. 2015;46(6):2497\u2013505.","journal-title":"Int J Oncol"},{"issue":"16","key":"1909_CR51","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/onc.2010.568","volume":"30","author":"Y Kotake","year":"2011","unstructured":"Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, et al. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene. 2011;30(16):1956\u201362.","journal-title":"Oncogene"},{"issue":"11","key":"1909_CR52","first-page":"20565","volume":"8","author":"E Liu","year":"2015","unstructured":"Liu E, Liu Z, Zhou Y, Mi R, Wang D. Overexpression of long non-coding RNA PVT1 in ovarian cancer cells promotes cisplatin resistance by regulating apoptotic pathways. Int J Clin Exp Med. 2015;8(11):20565\u201372.","journal-title":"Int J Clin Exp Med"},{"issue":"19","key":"1909_CR53","doi-asserted-by":"publisher","first-page":"5745","DOI":"10.1158\/1078-0432.CCR-06-2882","volume":"13","author":"Y Guan","year":"2007","unstructured":"Guan Y, Kuo W-L, Stilwell JL, Takano H, Lapuk AV, Fridlyand J, et al. Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer. Clin Cancer Res. 2007;13(19):5745\u201355.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"1909_CR54","first-page":"3803","volume":"8","author":"E Liu","year":"2015","unstructured":"Liu E, Liu Z, Zhou Y. Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated LncRNA PVT1. Int J Clin Exp Pathol. 2015;8(4):3803.","journal-title":"Int J Clin Exp Pathol"},{"issue":"1","key":"1909_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-025-02113-1","volume":"16","author":"H Li","year":"2025","unstructured":"Li H, Fan T, Qin M, Chen S, Zhou W, Wu P, et al. ESM1 suppresses LncRNA GAS5\/miR-23a-3p\/PTEN axis to promote the cisplatin-chemotherapy resistance of ovarian cancer cells via activating the PI3K\/AKT pathway. Discov Oncol. 2025;16(1):327.","journal-title":"Discov Oncol"},{"key":"1909_CR56","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1186\/1471-2407-13-461","volume":"13","author":"KH Lu","year":"2013","unstructured":"Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu WQ, et al. Long non-coding RNA MEG3 inhibits NSCLC cells proliferation and induces apoptosis by affecting p53 expression. BMC Cancer. 2013;13:461.","journal-title":"BMC Cancer"},{"key":"1909_CR57","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12935-020-01259-y","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu Y, Xu Y, Ding L, Yu L, Zhang B, Wei D. LncRNA MEG3 suppressed the progression of ovarian cancer via sponging miR-30e-3p and regulating LAMA4 expression. Cancer Cell Int. 2020;20:181.","journal-title":"Cancer Cell Int"},{"key":"1909_CR58","doi-asserted-by":"crossref","unstructured":"Zhang L, Zhao F, Li W, Song G, Kasim V, Wu S. The biological roles and molecular mechanisms of long Non-Coding RNA MEG3 in the hallmarks of cancer. Cancers (Basel). 2022;14(24).","DOI":"10.3390\/cancers14246032"},{"issue":"36","key":"1909_CR59","doi-asserted-by":"publisher","first-page":"6163","DOI":"10.1038\/sj.onc.1207808","volume":"23","author":"T Kawakami","year":"2004","unstructured":"Kawakami T, Zhang C, Taniguchi T, Kim CJ, Okada Y, Sugihara H, et al. Characterization of loss-of-inactive X in Klinefelter syndrome and female-derived cancer cells. Oncogene. 2004;23(36):6163\u20139.","journal-title":"Oncogene"},{"issue":"10","key":"1909_CR60","first-page":"769","volume":"1","author":"K-C Huang","year":"2002","unstructured":"Huang K-C, Rao PH, Lau CC, Heard E, Ng S-K, Brown C, et al. Relationship of XIST expression and responses of ovarian cancer to chemotherapy. Mol Cancer Ther. 2002;1(10):769\u201376.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"1909_CR61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1093\/hmg\/ddu502","volume":"24","author":"Y Gao","year":"2015","unstructured":"Gao Y, Meng H, Liu S, Hu J, Zhang Y, Jiao T, et al. LncRNA-HOST2 regulates cell biological behaviors in epithelial ovarian cancer through a mechanism involving microRNA let-7b. Hum Mol Genet. 2015;24(3):841\u201352.","journal-title":"Hum Mol Genet"},{"key":"1909_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.785111","volume":"11","author":"X Wang","year":"2021","unstructured":"Wang X, Du ZW, Xu TM, Wang XJ, Li W, Gao JL, et al. HIF-1\u03b1 is a rational target for future ovarian cancer therapies. Front Oncol. 2021;11:785111.","journal-title":"Front Oncol"},{"key":"1909_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9394563","volume":"2021","author":"Y Wang","year":"2021","unstructured":"Wang Y, Ding M, Yuan X, Jiao R, Zhu D, Huang W, et al. LncRNA SNHG15 promotes ovarian cancer progression through regulated CDK6 via sponging miR-370-3p. Biomed Res Int. 2021;2021:9394563.","journal-title":"Biomed Res Int"},{"issue":"3","key":"1909_CR64","doi-asserted-by":"publisher","first-page":"656","DOI":"10.4143\/crt.2016.263","volume":"49","author":"GW Yim","year":"2017","unstructured":"Yim GW, Kim HJ, Kim LK, Kim SW, Kim S, Nam EJ, et al. Long non-coding RNA HOXA11 antisense promotes cell proliferation and invasion and predicts patient prognosis in serous ovarian cancer. Cancer Res Treat. 2017;49(3):656\u201368.","journal-title":"Cancer Res Treat"},{"issue":"28","key":"1909_CR65","doi-asserted-by":"publisher","first-page":"25381","DOI":"10.18632\/oncotarget.4541","volume":"6","author":"Z Cheng","year":"2015","unstructured":"Cheng Z, Guo J, Chen L, Luo N, Yang W, Qu X. A long noncoding RNA AB073614 promotes tumorigenesis and predicts poor prognosis in ovarian cancer. Oncotarget. 2015;6(28):25381\u20139.","journal-title":"Oncotarget"},{"issue":"1","key":"1909_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0671-2","volume":"16","author":"ES Hosseini","year":"2017","unstructured":"Hosseini ES, Meryet-Figuiere M, Sabzalipoor H, Kashani HH, Nikzad H, Asemi Z. Dysregulated expression of long noncoding RNAs in gynecologic cancers. Mol Cancer. 2017;16(1):107.","journal-title":"Mol Cancer"},{"key":"1909_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-13-3","volume":"13","author":"B Gloss","year":"2014","unstructured":"Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, et al. ZNF300P1 encodes a LincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer. 2014;13:3.","journal-title":"Mol Cancer"},{"issue":"1","key":"1909_CR68","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1476-4598-13-3","volume":"13","author":"B Gloss","year":"2014","unstructured":"Gloss B, Moran-Jones K, Lin V, Gonzalez M, Scurry J, Hacker NF, et al. ZNF300P1 encodes a LincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer. 2014;13(1):3.","journal-title":"Mol Cancer"},{"issue":"2","key":"1909_CR69","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.yexmp.2016.09.008","volume":"101","author":"D Kuang","year":"2016","unstructured":"Kuang D, Zhang X, Hua S, Dong W, Li Z. Long non-coding RNA TUG1 regulates ovarian cancer proliferation and metastasis via affecting epithelial-mesenchymal transition. Exp Mol Pathol. 2016;101(2):267\u201373.","journal-title":"Exp Mol Pathol"},{"key":"1909_CR70","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12935-018-0604-1","volume":"18","author":"Y Mu","year":"2018","unstructured":"Mu Y, Li N, Cui YL. The LncRNA CCAT1 upregulates TGF\u03b2R1 via sponging miR-490-3p to promote TGF\u03b21-induced EMT of ovarian cancer cells. Cancer Cell Int. 2018;18:145.","journal-title":"Cancer Cell Int"},{"issue":"2","key":"1909_CR71","first-page":"322","volume":"22","author":"XJ Lai","year":"2018","unstructured":"Lai XJ, Cheng HF. LncRNA colon cancer-associated transcript 1 (CCAT1) promotes proliferation and metastasis of ovarian cancer via miR-1290. Eur Rev Med Pharmacol Sci. 2018;22(2):322\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"4","key":"1909_CR72","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/kjm2.12335","volume":"37","author":"LJ Liu","year":"2021","unstructured":"Liu LJ, Sun XY, Yang CX, Zou XY. MiR-10a-5p restrains the aggressive phenotypes of ovarian cancer cells by inhibiting HOXA1. Kaohsiung J Med Sci. 2021;37(4):276\u201385.","journal-title":"Kaohsiung J Med Sci"},{"issue":"55","key":"1909_CR73","doi-asserted-by":"publisher","first-page":"30552","DOI":"10.18632\/oncotarget.25702","volume":"9","author":"BQ Guo","year":"2018","unstructured":"Guo BQ, Lu WQ. The prognostic significance of high\/positive expression of tissue VEGF in ovarian cancer. Oncotarget. 2018;9(55):30552\u201360.","journal-title":"Oncotarget"},{"issue":"12","key":"1909_CR74","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/nrc3627","volume":"13","author":"HL Goel","year":"2013","unstructured":"Goel HL, Mercurio AM. VEGF targets the tumour cell. Nat Rev Cancer. 2013;13(12):871\u201382.","journal-title":"Nat Rev Cancer"},{"issue":"16","key":"1909_CR75","doi-asserted-by":"publisher","first-page":"3912","DOI":"10.1158\/0008-5472.CAN-11-4058","volume":"72","author":"Y Cao","year":"2012","unstructured":"Cao Y, E G, Wang E, Pal K, Dutta SK, Bar-Sagi D, et al. VEGF exerts an angiogenesis-independent function in cancer cells to promote their malignant progression. Cancer Res. 2012;72(16):3912\u20138.","journal-title":"Cancer Res"},{"issue":"4","key":"1909_CR76","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10456-006-9055-8","volume":"9","author":"M Shibuya","year":"2006","unstructured":"Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1\/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9(4):225\u201330. discussion 31.","journal-title":"Angiogenesis"},{"issue":"12","key":"1909_CR77","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1177\/1947601911423031","volume":"2","author":"M Shibuya","year":"2011","unstructured":"Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097\u2013105.","journal-title":"Genes Cancer"},{"issue":"6","key":"1909_CR78","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1182\/blood.V99.6.2179","volume":"99","author":"S Dias","year":"2002","unstructured":"Dias S, Choy M, Alitalo K, Rafii S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood. 2002;99(6):2179\u201384.","journal-title":"Blood"},{"issue":"10","key":"1909_CR79","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-023-03719-4","volume":"13","author":"S Vimalraj","year":"2023","unstructured":"Vimalraj S, Hariprabu KNG, Rahaman M, Govindasami P, Perumal K, Sekaran S, et al. Vascular endothelial growth factor-C and its receptor-3 signaling in tumorigenesis. 3 Biotech. 2023;13(10):326.","journal-title":"3 Biotech"},{"issue":"2","key":"1909_CR80","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/sj.bjc.6600701","volume":"88","author":"Y Yokoyama","year":"2003","unstructured":"Yokoyama Y, Charnock-Jones DS, Licence D, Yanaihara A, Hastings JM, Holland CM, et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer. 2003;88(2):237\u201344.","journal-title":"Br J Cancer"},{"issue":"2","key":"1909_CR81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ceb.2008.12.012","volume":"21","author":"M Lohela","year":"2009","unstructured":"Lohela M, Bry M, Tammela T, Alitalo K. VEGFs and receptors involved in angiogenesis versus lymphangiogenesis. Curr Opin Cell Biol. 2009;21(2):154\u201365.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"1909_CR82","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02249-0","volume":"10","author":"C Lee","year":"2025","unstructured":"Lee C, Kim MJ, Kumar A, Lee HW, Yang Y, Kim Y. Vascular endothelial growth factor signaling in health and disease: from molecular mechanisms to therapeutic perspectives. Signal Transduct Target Ther. 2025;10(1):170.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1909_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2023.188888","volume":"1878","author":"V Bhardwaj","year":"2023","unstructured":"Bhardwaj V, Zhang X, Pandey V, Garg M. Neo-vascularization-based therapeutic perspectives in advanced ovarian cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2023;1878(3):188888.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"3","key":"1909_CR84","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2147\/vhrm.2006.2.3.213","volume":"2","author":"N Nishida","year":"2006","unstructured":"Nishida N, Yano H, Nishida T, Kamura T, Kojiro M. Angiogenesis in cancer. Vasc Health Risk Manag. 2006;2(3):213\u20139.","journal-title":"Vasc Health Risk Manag"},{"issue":"Suppl 3","key":"1909_CR85","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000088478","volume":"69","author":"P Carmeliet","year":"2005","unstructured":"Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology. 2005;69(Suppl 3):4\u201310.","journal-title":"Oncology"},{"issue":"8","key":"1909_CR86","doi-asserted-by":"publisher","first-page":"15885","DOI":"10.3390\/ijms140815885","volume":"14","author":"NG Gavalas","year":"2013","unstructured":"Gavalas NG, Liontos M, Trachana SP, Bagratuni T, Arapinis C, Liacos C, et al. Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci. 2013;14(8):15885\u2013909.","journal-title":"Int J Mol Sci"},{"key":"1909_CR87","doi-asserted-by":"crossref","unstructured":"Wee P, Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers (Basel). 2017;9(5).","DOI":"10.3390\/cancers9050052"},{"issue":"4","key":"1909_CR88","doi-asserted-by":"publisher","first-page":"8213","DOI":"10.3390\/ijms14048213","volume":"14","author":"ZC Dobbin","year":"2013","unstructured":"Dobbin ZC, Landen CN. The importance of the PI3K\/AKT\/MTOR pathway in the progression of ovarian cancer. Int J Mol Sci. 2013;14(4):8213\u201327.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1909_CR89","doi-asserted-by":"publisher","first-page":"227","DOI":"10.3233\/HAB-200411","volume":"28","author":"P Maleki","year":"2020","unstructured":"Maleki P, Sheida SV, Mowla SJ, Soleimani V, Taheri M, Raheb J. LINK-a long non-coding RNA and VEGF RNA expression in epithelial ovarian cancer patients. Hum Antibodies. 2020;28(3):227\u201332.","journal-title":"Hum Antibodies"},{"issue":"1","key":"1909_CR90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/iub.2620","volume":"75","author":"G Fontemaggi","year":"2023","unstructured":"Fontemaggi G. Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer. IUBMB Life. 2023;75(1):30\u20139.","journal-title":"IUBMB Life"},{"key":"1909_CR91","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.biopha.2017.12.064","volume":"98","author":"T Liu","year":"2018","unstructured":"Liu T, Yu T, Hu H, He K. Knockdown of the long non-coding RNA HOTTIP inhibits colorectal cancer cell proliferation and migration and induces apoptosis by targeting SGK1. Biomed Pharmacother. 2018;98:286\u201396.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"1909_CR92","doi-asserted-by":"publisher","first-page":"263","DOI":"10.4183\/aeb.2022.263","volume":"18","author":"S Zhang","year":"2022","unstructured":"Zhang S, Ma Q, Wu X, Chen P. LncRNA HOTTIP promotes ovarian cancer cell invasion and metastasis by stabilizing HIF-1\u03b1 in the anoxic cellular microenvironment. Acta Endocrinol (Buchar). 2022;18(3):263\u201370.","journal-title":"Acta Endocrinol (Buchar)"},{"key":"1909_CR93","doi-asserted-by":"publisher","first-page":"e922012","DOI":"10.12659\/MSM.922012","volume":"26","author":"X Wu","year":"2020","unstructured":"Wu X, Wang Y, Zhong W, Cheng H, Tian Z. The long non-coding RNA MALAT1 enhances ovarian cancer cell stemness by inhibiting YAP translocation from nucleus to cytoplasm. Med Sci Monit. 2020;26:e922012.","journal-title":"Med Sci Monit"},{"issue":"1","key":"1909_CR94","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bbrc.2019.03.141","volume":"514","author":"Y Wang","year":"2019","unstructured":"Wang Y, Huang Y, Liu H, Su D, Luo F, Zhou F. Long noncoding RNA CDKN2B-AS1 interacts with miR-411-3p to regulate ovarian cancer in vitro and in vivo through HIF-1a\/VEGF\/P38 pathway. Biochem Biophys Res Commun. 2019;514(1):44\u201350.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"1909_CR95","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ygyno.2012.11.002","volume":"128","author":"L Yu","year":"2013","unstructured":"Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;128(2):391\u20136.","journal-title":"Gynecol Oncol"},{"issue":"18","key":"1909_CR96","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1091\/mbc.e12-03-0206","volume":"23","author":"V Tripathi","year":"2012","unstructured":"Tripathi V, Song DY, Zong X, Shevtsov SP, Hearn S, Fu XD, et al. SRSF1 regulates the assembly of pre-mRNA processing factors in nuclear speckles. Mol Biol Cell. 2012;23(18):3694\u2013706.","journal-title":"Mol Biol Cell"},{"key":"1909_CR97","doi-asserted-by":"publisher","first-page":"1527309","DOI":"10.3389\/fcell.2025.1527309","volume":"13","author":"S Zhang","year":"2025","unstructured":"Zhang S, Zhang Y, Feng S, Han M, Wang Z, Qiao D, et al. Tumor-promoting effect and tumor immunity of SRSFs. Front Cell Dev Biol. 2025;13:1527309.","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"1909_CR98","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.molcel.2010.08.011","volume":"39","author":"V Tripathi","year":"2010","unstructured":"Tripathi V, Ellis JD, Shen Z, Song DY, Pan Q, Watt AT, et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell. 2010;39(6):925\u201338.","journal-title":"Mol Cell"},{"issue":"4","key":"1909_CR99","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s10456-004-8272-2","volume":"7","author":"Y Wang","year":"2004","unstructured":"Wang Y, Fei D, Vanderlaan M, Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis. 2004;7(4):335\u201345.","journal-title":"Angiogenesis"},{"issue":"2","key":"1909_CR100","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.bbrc.2005.05.132","volume":"333","author":"N Ferrara","year":"2005","unstructured":"Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun. 2005;333(2):328\u201335.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"1909_CR101","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189374","volume":"1880","author":"E Grillo","year":"2025","unstructured":"Grillo E, Romani C, Ettorre VM, Santin AD, Mitola S. The VEGF\/VEGFR2 system in ovarian cancer: from functional to pharmacological significance. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(4):189374.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"4","key":"1909_CR102","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS. Small molecule inhibitors targeting the cancers. MedComm (2020). 2022;3(4):e181.","journal-title":"MedComm (2020)"},{"issue":"1","key":"1909_CR103","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0718-5","volume":"12","author":"S Qin","year":"2019","unstructured":"Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy. J Hematol Oncol. 2019;12(1):27.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"1909_CR104","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1007\/s11912-013-0368-7","volume":"16","author":"KK Ciombor","year":"2014","unstructured":"Ciombor KK, Berlin J. Aflibercept\u2013a decoy VEGF receptor. Curr Oncol Rep. 2014;16(2):368.","journal-title":"Curr Oncol Rep"},{"issue":"2","key":"1909_CR105","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"N Papadopoulos","year":"2012","unstructured":"Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171\u201385.","journal-title":"Angiogenesis"},{"key":"1909_CR106","doi-asserted-by":"crossref","unstructured":"Leong A, Kim M. The Angiopoietin-2 and TIE pathway as a therapeutic target for enhancing antiangiogenic therapy and immunotherapy in patients with advanced cancer. Int J Mol Sci. 2020;21(22).","DOI":"10.3390\/ijms21228689"},{"issue":"6","key":"1909_CR107","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1038\/s41416-023-02326-7","volume":"129","author":"D Bhamidipati","year":"2023","unstructured":"Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. PARP inhibitors: enhancing efficacy through rational combinations. Br J Cancer. 2023;129(6):904\u201316.","journal-title":"Br J Cancer"},{"issue":"2","key":"1909_CR108","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.ygyno.2021.05.018","volume":"162","author":"A Alvarez Secord","year":"2021","unstructured":"Alvarez Secord A, O\u2019Malley DM, Sood AK, Westin SN, Liu JF. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: a review. Gynecol Oncol. 2021;162(2):482\u201395.","journal-title":"Gynecol Oncol"},{"key":"1909_CR109","doi-asserted-by":"publisher","first-page":"1372077","DOI":"10.3389\/fphar.2024.1372077","volume":"15","author":"Y Wei","year":"2024","unstructured":"Wei Y, He L, Liu T, Guo T, Xie C, Jia J, et al. Efficacy and safety of PARP inhibitors combined with antiangiogenic agents in the maintenance treatment of ovarian cancer: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Front Pharmacol. 2024;15:1372077.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1909_CR110","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5306\/wjco.v8.i2.120","volume":"8","author":"V Masoud","year":"2017","unstructured":"Masoud V, Pag\u00e8s G. Targeted therapies in breast cancer: new challenges to fight against resistance. World J Clin Oncol. 2017;8(2):120\u201334.","journal-title":"World J Clin Oncol"},{"issue":"4","key":"1909_CR111","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.ccr.2005.09.016","volume":"8","author":"RS Kerbel","year":"2005","unstructured":"Kerbel RS. Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. Cancer Cell. 2005;8(4):269\u201371.","journal-title":"Cancer Cell"},{"key":"1909_CR112","volume-title":"Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF","author":"AM Duffy","year":"2013","unstructured":"Duffy AM, Bouchier-Hayes DJ, Harmey JH. Vascular endothelial growth factor (VEGF) and its role in non-endothelial cells: autocrine signalling by VEGF. Madame Curie Bioscience Database: Landes Bioscience; 2013."},{"issue":"5","key":"1909_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189396","volume":"1880","author":"P Garg","year":"2025","unstructured":"Garg P, Singhal G, Horne D, Salgia R, Singhal SS. Metabolic reprogramming in breast cancer: pathways driving progression, drug resistance, and emerging therapeutics. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 2025;1880(5):189396.","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"1","key":"1909_CR114","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y, Shi H, Zhou W. Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):70.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"1909_CR115","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02165-x","volume":"23","author":"S Liu","year":"2024","unstructured":"Liu S, Zhang X, Wang W, Li X, Sun X, Zhao Y, et al. Metabolic reprogramming and therapeutic resistance in primary and metastatic breast cancer. Mol Cancer. 2024;23(1):261.","journal-title":"Mol Cancer"},{"issue":"1","key":"1909_CR116","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","volume":"21","author":"A Emami Nejad","year":"2021","unstructured":"Emami Nejad A, Najafgholian S, Rostami A, Sistani A, Shojaeifar S, Esparvarinha M, et al. The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment. Cancer Cell Int. 2021;21(1):62.","journal-title":"Cancer Cell Int"},{"issue":"17","key":"1909_CR117","doi-asserted-by":"publisher","first-page":"5822","DOI":"10.1158\/1078-0432.CCR-11-1185","volume":"17","author":"C Carbone","year":"2011","unstructured":"Carbone C, Moccia T, Zhu C, Paradiso G, Budillon A, Chiao PJ, et al. Anti-VEGF treatment-resistant pancreatic cancers secrete proinflammatory factors that contribute to malignant progression by inducing an EMT cell phenotype. Clin Cancer Res. 2011;17(17):5822\u201332.","journal-title":"Clin Cancer Res"},{"key":"1909_CR118","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/HP.S93413","volume":"3","author":"B Muz","year":"2015","unstructured":"Muz B, de la Puente P, Azab F, Azab AK. The role of hypoxia in cancer progression, angiogenesis, metastasis, and resistance to therapy. Hypoxia (Auckl). 2015;3:83\u201392.","journal-title":"Hypoxia (Auckl)"},{"key":"1909_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115622","volume":"167","author":"D Gao","year":"2023","unstructured":"Gao D, Fang L, Liu C, Yang M, Yu X, Wang L, et al. Microenvironmental regulation in tumor progression: interactions between cancer-associated fibroblasts and immune cells. Biomedicine & Pharmacotherapy. 2023;167:115622.","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"3","key":"1909_CR120","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"4","key":"1909_CR121","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s13402-024-00931-z","volume":"47","author":"D Coursier","year":"2024","unstructured":"Coursier D, Calvo F. CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance. Cell Oncol (Dordr). 2024;47(4):1091\u2013112.","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"1909_CR122","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1161\/HYPERTENSIONAHA.117.08856","volume":"70","author":"RM Touyz","year":"2017","unstructured":"Touyz RM, Lang NN, Herrmann J, van den Meiracker AH, Danser AHJ. Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension. 2017;70(2):220\u20136.","journal-title":"Hypertension"},{"issue":"4","key":"1909_CR123","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11912-012-0242-z","volume":"14","author":"SR Hayman","year":"2012","unstructured":"Hayman SR, Leung N, Grande JP, Garovic VD. VEGF inhibition, hypertension, and renal toxicity. Curr Oncol Rep. 2012;14(4):285\u201394.","journal-title":"Curr Oncol Rep"},{"issue":"6","key":"1909_CR124","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.semnephrol.2010.09.007","volume":"30","author":"ES Robinson","year":"2010","unstructured":"Robinson ES, Khankin EV, Karumanchi SA, Humphreys BD. Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol. 2010;30(6):591\u2013601.","journal-title":"Semin Nephrol"},{"issue":"12","key":"1909_CR125","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1038\/sj.bjc.6603813","volume":"96","author":"T Kamba","year":"2007","unstructured":"Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96(12):1788\u201395.","journal-title":"Br J Cancer"},{"key":"1909_CR126","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fcell.2020.00584","volume":"8","author":"C Montemagno","year":"2020","unstructured":"Montemagno C, Pag\u00e8s G. Resistance to anti-angiogenic therapies: a mechanism depending on the time of exposure to the drugs. Front Cell Dev Biol. 2020;8:584.","journal-title":"Front Cell Dev Biol"},{"issue":"3","key":"1909_CR127","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nbt.3765","volume":"35","author":"A Khvorova","year":"2017","unstructured":"Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies of clinical utility. Nat Biotechnol. 2017;35(3):238\u201348.","journal-title":"Nat Biotechnol"},{"key":"1909_CR128","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118525","volume":"263","author":"A Hazafa","year":"2020","unstructured":"Hazafa A, Mumtaz M, Farooq MF, Bilal S, Chaudhry SN, Firdous M, et al. CRISPR\/Cas9: A powerful genome editing technique for the treatment of cancer cells with present challenges and future directions. Life Sci. 2020;263:118525.","journal-title":"Life Sci"},{"key":"1909_CR129","doi-asserted-by":"publisher","first-page":"894305","DOI":"10.3389\/fcell.2022.894305","volume":"10","author":"R Giordo","year":"2022","unstructured":"Giordo R, Wehbe Z, Posadino AM, Erre GL, Eid AH, Mangoni AA, et al. Disease-associated regulation of non-coding RNAs by resveratrol: molecular insights and therapeutic applications. Front Cell Dev Biol. 2022;10:894305.","journal-title":"Front Cell Dev Biol"},{"issue":"44","key":"1909_CR130","doi-asserted-by":"publisher","first-page":"78208","DOI":"10.18632\/oncotarget.20596","volume":"8","author":"M Nowacki","year":"2017","unstructured":"Nowacki M, Peterson M, Kloskowski T, McCabe E, Guiral DC, Polom K, et al. Nanoparticle as a novel tool in hyperthermic intraperitoneal and pressurized intraperitoneal aerosol chemotheprapy to treat patients with peritoneal carcinomatosis. Oncotarget. 2017;8(44):78208.","journal-title":"Oncotarget"},{"issue":"2","key":"1909_CR131","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1021\/mp500628g","volume":"12","author":"M Ocak","year":"2015","unstructured":"Ocak M, Gillman AG, Bresee J, Zhang L, Vlad AM, M\u00fcller C, et al. Folate receptor-targeted multimodality imaging of ovarian cancer in a novel syngeneic mouse model. Mol Pharm. 2015;12(2):542\u201353.","journal-title":"Mol Pharm"},{"issue":"13","key":"1909_CR132","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32(13):1302\u20138.","journal-title":"J Clin Oncol"},{"issue":"26","key":"1909_CR133","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365(26):2484\u201396.","journal-title":"N Engl J Med"},{"issue":"26","key":"1909_CR134","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.19.01009","volume":"37","author":"KS Tewari","year":"2019","unstructured":"Tewari KS, Burger RA, Enserro D, Norquist BM, Swisher EM, Brady MF, et al. Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer. J Clin Oncol. 2019;37(26):2317\u201328.","journal-title":"J Clin Oncol"},{"key":"1909_CR135","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1756-8722-1-11","volume":"1","author":"D Chu","year":"2008","unstructured":"Chu D, Wu S. Novel therapies in genitourinary cancer: an update. J Hematol Oncol. 2008;1:11.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"1909_CR136","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0199-6","volume":"5","author":"Q Wang","year":"2020","unstructured":"Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies in gynecological cancers: a comprehensive review of clinical evidence. Signal Transduct Target Ther. 2020;5(1):137.","journal-title":"Signal Transduct Target Ther"},{"issue":"10023","key":"1909_CR137","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S0140-6736(15)01167-8","volume":"387","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Embleton AC, Raja F, Perren TJ, Jayson GC, Rustin GJ, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;387(10023):1066\u201374.","journal-title":"Lancet"},{"issue":"2","key":"1909_CR138","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ygyno.2019.08.024","volume":"155","author":"I Vergote","year":"2019","unstructured":"Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, et al. Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol. 2019;155(2):186\u201391.","journal-title":"Gynecol Oncol"},{"issue":"30","key":"1909_CR139","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A du Bois","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374\u201382.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1909_CR140","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(15)00366-6","volume":"17","author":"A du Bois","year":"2016","unstructured":"du Bois A, Kristensen G, Ray-Coquard I, Reuss A, Pignata S, Colombo N, et al. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2016;17(1):78\u201389.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1909_CR141","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/S1470-2045(14)70244-X","volume":"15","author":"BJ Monk","year":"2014","unstructured":"Monk BJ, Poveda A, Vergote I, Raspagliesi F, Fujiwara K, Bae DS, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15(8):799\u2013808.","journal-title":"Lancet Oncol"},{"issue":"1","key":"1909_CR142","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2011.11.021","volume":"125","author":"N Colombo","year":"2012","unstructured":"Colombo N, Mangili G, Mammoliti S, Kalling M, Tholander B, Sternas L, et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol. 2012;125(1):42\u20137.","journal-title":"Gynecol Oncol"},{"issue":"9","key":"1909_CR143","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/S1470-2045(18)30372-3","volume":"19","author":"R Chekerov","year":"2018","unstructured":"Chekerov R, Hilpert F, Mahner S, El-Balat A, Harter P, De Gregorio N, et al. Sorafenib plus topotecan versus placebo plus topotecan for platinum-resistant ovarian cancer (TRIAS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19(9):1247\u201358.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1909_CR144","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1093\/annonc\/mdq357","volume":"22","author":"J Biagi","year":"2011","unstructured":"Biagi J, Oza A, Chalchal H, Grimshaw R, Ellard S, Lee U, et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study. Ann Oncol. 2011;22(2):335\u201340.","journal-title":"Ann Oncol"},{"issue":"1","key":"1909_CR145","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13048-022-01055-4","volume":"16","author":"Z Pan","year":"2023","unstructured":"Pan Z, Luo Z, He H, Chen Y, Zhao B, Yang Z, et al. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer. J Ovarian Res. 2023;16(1):44.","journal-title":"J Ovarian Res"},{"key":"1909_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1175","volume":"32","author":"J Chen","year":"2021","unstructured":"Chen J, Wei W, Zheng L, Li H, Feng Y, Wan T, et al. 732P anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: a single-arm, open-label, phase II study. Ann Oncol. 2021;32:S734.","journal-title":"Ann Oncol"},{"key":"1909_CR147","doi-asserted-by":"publisher","first-page":"9857","DOI":"10.2147\/OTT.S268613","volume":"13","author":"J Ni","year":"2020","unstructured":"Ni J, Cheng X, Chen J, Guo W, Dai Z. Anlotinib as exploratory therapy for platinum-resistant ovarian cancer: a retrospective study on efficacy and safety. Onco Targets Ther. 2020;13:9857\u201363.","journal-title":"Onco Targets Ther"},{"issue":"7","key":"1909_CR148","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100689","volume":"3","author":"CY Lan","year":"2022","unstructured":"Lan CY, Zhao J, Yang F, Xiong Y, Li R, Huang Y, et al. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: a multi-center, single-arm, phase 1b trial. Cell Rep Med. 2022;3(7):100689.","journal-title":"Cell Rep Med"},{"issue":"5","key":"1909_CR149","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1200\/JCO.22.01021","volume":"41","author":"V Makker","year":"2023","unstructured":"Makker V, Aghajanian C, Cohn AL, Romeo M, Bratos R, Brose MS, et al. A phase Ib\/II study of lenvatinib and pembrolizumab in advanced endometrial carcinoma (Study 111\/KEYNOTE-146): long-term efficacy and safety update. J Clin Oncol. 2023;41(5):974\u20139.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1909_CR150","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s10020-021-00421-0","volume":"27","author":"J Yang","year":"2021","unstructured":"Yang J, Qi M, Fei X, Wang X, Wang K. Long non-coding RNA XIST: a novel oncogene in multiple cancers. Mol Med. 2021;27(1):159.","journal-title":"Mol Med"},{"issue":"1","key":"1909_CR151","doi-asserted-by":"publisher","DOI":"10.1186\/s10020-025-01205-6","volume":"31","author":"W Zhang","year":"2025","unstructured":"Zhang W, Xia M, Li J, Liu G, Sun Y, Chen X, et al. Warburg effect and lactylation in cancer: mechanisms for chemoresistance. Mol Med. 2025;31(1):146.","journal-title":"Mol Med"},{"key":"1909_CR152","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.omtn.2020.06.028","volume":"21","author":"Y Wang","year":"2020","unstructured":"Wang Y, Chen R, Zhou X, Guo R, Yin J, Li Y, et al. MiR-137: a novel therapeutic target for human glioma. Mol Ther Nucleic Acids. 2020;21:614\u201322.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"4","key":"1909_CR153","volume":"1880","author":"E Grillo","year":"2025","unstructured":"Grillo E, Romani C, Ettorre VM, Santin AD, Mitola S. The VEGF\/VEGFR2 system in ovarian cancer: from functional to pharmacological significance. Biochimica et Biophysica Acta (BBA). 2025;1880(4):189374.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"issue":"1","key":"1909_CR154","doi-asserted-by":"publisher","first-page":"29651","DOI":"10.1038\/s41598-025-15439-1","volume":"15","author":"W Hu","year":"2025","unstructured":"Hu W, Wu B, Chen Y, Guo X, Wang X, Wang D. Prognostic and therapeutic relevance of IL2RG-related LncRNAs in clear cell renal cell carcinoma. Sci Rep. 2025;15(1):29651.","journal-title":"Sci Rep"},{"issue":"1","key":"1909_CR155","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06732-8","volume":"23","author":"D Zhang","year":"2025","unstructured":"Zhang D, Pei S, Feng Z, Xia G. Functions and mechanisms of lncRNAs in immune escape and their application in immunotherapy for colorectal cancer. J Transl Med. 2025;23(1):689.","journal-title":"J Transl Med"},{"key":"1909_CR156","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.omtn.2022.03.012","volume":"28","author":"J Liu","year":"2022","unstructured":"Liu J, Zhang Q, Yang D, Xie F, Wang Z. The role of long non-coding RNAs in angiogenesis and anti-angiogenic therapy resistance in cancer. Mol Ther Nucleic Acids. 2022;28:397\u2013407.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"1909_CR157","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s10014-024-00481-0","volume":"41","author":"T Ezaki","year":"2024","unstructured":"Ezaki T, Tanaka T, Tamura R, Ohara K, Yamamoto Y, Takei J, et al. Status of alternative angiogenic pathways in glioblastoma resected under and after bevacizumab treatment. Brain Tumor Pathol. 2024;41(2):61\u201372.","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"1909_CR158","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02299-4","volume":"10","author":"S Singh","year":"2025","unstructured":"Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10(1):213.","journal-title":"Signal Transduct Target Ther"},{"key":"1909_CR159","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/4880355","volume":"2022","author":"C Jin","year":"2022","unstructured":"Jin C, Yuan M, Bu H, Jin C. Antiangiogenic strategies in epithelial ovarian cancer: mechanism, resistance, and combination therapy. J Oncol. 2022;2022:4880355.","journal-title":"J Oncol"},{"key":"1909_CR160","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221118010","volume":"14","author":"M Chen","year":"2022","unstructured":"Chen M, Lei N, Tian W, Li Y, Chang L. Recent advances of non-coding RNAs in ovarian cancer prognosis and therapeutics. Ther Adv Med Oncol. 2022;14:17588359221118010.","journal-title":"Ther Adv Med Oncol"},{"issue":"7","key":"1909_CR161","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70243","volume":"6","author":"T Wolde","year":"2025","unstructured":"Wolde T, Bhardwaj V, Pandey V. Current bioinformatics tools in precision oncology. MedComm. 2025;6(7):e70243.","journal-title":"MedComm"},{"key":"1909_CR162","doi-asserted-by":"crossref","unstructured":"Wolde T, Bhardwaj V, Reyad-Ul-Ferdous M, Qin P, Pandey V. The integrated bioinformatic approach reveals the prognostic significance of LRP1 expression in ovarian cancer. Int J Mol Sci. 2024;25(14).","DOI":"10.3390\/ijms25147996"},{"key":"1909_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123113","volume":"357","author":"P Huang","year":"2024","unstructured":"Huang P, Wolde T, Bhardwaj V, Zhang X, Pandey V. TFF3 and PVRL2 co-targeting identified by multi-omics approach as an effective cancer immunosuppression strategy. Life Sci. 2024;357:123113.","journal-title":"Life Sci"},{"key":"1909_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.852746","volume":"12","author":"V Bhardwaj","year":"2022","unstructured":"Bhardwaj V, Sharma A, Parambath SV, Gul I, Zhang X, Lobie PE, et al. Machine learning for endometrial cancer prediction and prognostication. Front Oncol. 2022;12:852746.","journal-title":"Front Oncol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-025-01909-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-025-01909-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T13:02:55Z","timestamp":1772629375000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-025-01909-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":164,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1186\/s13048-025-01909-7","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"86"}}